Lilly has 'no intention' of animal health spinoff; NICE rejects first-line Xtandi;

@FiercePharma: India competition body cracks down on GSK, Sanofi. More | Follow @FiercePharma

@EricPFierce: Patheon was a $1.7B company in its first year as it set out to change the CDMO market. Story | Follow @EricPFierce

@CarlyHFierce: Teva amps up Mylan stake again, winning agenda rights for upcoming annual meeting. Story | Follow @CarlyHFierce

> Responding to analyst speculation about a potential move, Eli Lilly & Co. ($LLY) said it has no interest in spinning off its animal health unit. Report

> Cost-effectiveness gatekeepers in England released draft guidance rejecting Astellas' prostate cancer drug Xtandi in patients who haven't been previously treated with chemotherapy. Report

> Indian sources say Novartis ($NVS) is considering delisting its local unit from the stock market; the Swiss drugmaker already owns 75% of the company. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Finnish headset light therapy via the ear canal cut jet lag time in half in study. Article | Follow @FierceMedDev

@VarunSaxena2: U.K. researchers say earlier diagnoses of bladder cancer needed, especially among women. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: After stalling for months, NHS England pledges £190M for new hep C treatments. More | Follow @EmilyWFierce

> Hospira execs called 'shameful' for denying cybersecurity risks posed by their infusion pumps. More

> China-U.S. bridging investor Ally Bridge Group discloses 6 recent med tech investments. Story

Biotech News

@FierceBiotech: Unum hits the gas on next-gen CAR-T tech after banking $65M round. Article | Follow @FierceBiotech

@JohnCFierce: Fun note: Unum CEO Wilson is former deals chief for $NVS. I told him that w/ that background, I was amazed he could talk to anyone in media. | Follow @JohnCFierce

@DamianFierce: Pay $5 million, wait 6 months, make $315 million. Biotech! Report | Follow @DamianFierce

> Why Axovant's $315M IPO bonanza should scare the hell out of you. More

> J&J's global hunt for new drugs, cool new tech spurs 17 new deals. Article

> Infants with rare cases of SMA get stronger, live longer on Isis drug. Story

Vaccines News

> India competition body cracks down on GSK, Sanofi. Report

> Whistleblowers accuse Merck of withholding info on mumps vaccine. More

> Abivax eyes $49M IPO to advance Cuban-made hep B vaccine. Story

> India, Netherlands partner for vaccines development. Item

> One dose of GlaxoSmithKline's Cervarix may suffice. Article

CRO News

> TFS takes the plunge on a risk-sharing deal for a Parkinson's drug. More

> ContraVir recruits CRO ImageIQ for shingles trial. Item

> WuXi signs on to help ReGenX manufacture gene therapies. Story

> Synexus looks to widen its footprint after $128M PE deal. Article

> INC wants to hear from trial sites on how to improve R&D. Report

Pharma Manufacturing News

> Teva builds its Mylan stake in effort toward becoming generics colossus. Item

> South African regulator eases API oversight rules in face of shortages. Story

> California company buys facility for stem cell manufacturing. More

> South Florida men go to prison for $2.2M Mucinex heist. Story

> Sandoz recalls 1M units of generic Zyrtec made in India. Article

Pharma Asia News

> India to exempt some AIDS, TB drugs, and diagnostics from import taxes. Item

> China part of Opdivo combo trial plans as Nasdaq-listed CBMG buys cancer vaccine. Report

> China's Great Firewall flummoxes European businesses, and others. Story

> Two key Alcon Asia-focused executives fired in regional shakeup. Article

> Samsung Bioepis, Celltrion propel South Korea to front ranks of biosimilar race. More

And Finally... San Francisco may become the first U.S. city to put health warnings on ads for sugary sodas. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.